154 related articles for article (PubMed ID: 37042147)
21. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
[TBL] [Abstract][Full Text] [Related]
22. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Xu H; Dong X; Zhao H; Hou T; Chen C; Chen G; Ye J; Li Y
J Clin Lab Anal; 2021 Mar; 35(3):e23696. PubMed ID: 33434308
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
25. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
[TBL] [Abstract][Full Text] [Related]
26. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC.
Sughayer MA; Alnaimy F; Alsughayer AM; Qamhia N
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):663-666. PubMed ID: 30024424
[TBL] [Abstract][Full Text] [Related]
28. Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.
Fernandez AI; Gaule P; Rimm DL
Mod Pathol; 2023 Jul; 36(7):100159. PubMed ID: 36925070
[TBL] [Abstract][Full Text] [Related]
29. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.
Hendry S; Byrne DJ; Wright GM; Young RJ; Sturrock S; Cooper WA; Fox SB
J Thorac Oncol; 2018 Mar; 13(3):367-376. PubMed ID: 29175115
[TBL] [Abstract][Full Text] [Related]
32. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
[TBL] [Abstract][Full Text] [Related]
34. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Nambirajan A; Husain N; Shukla S; Kumar S; Jain D
Indian J Med Res; 2019 Oct; 150(4):376-384. PubMed ID: 31823919
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
36. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
[TBL] [Abstract][Full Text] [Related]
37. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
Front Immunol; 2022; 13():954910. PubMed ID: 35967344
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Brunnström H; Johansson A; Westbom-Fremer S; Backman M; Djureinovic D; Patthey A; Isaksson-Mettävainio M; Gulyas M; Micke P
Mod Pathol; 2017 Oct; 30(10):1411-1421. PubMed ID: 28664936
[TBL] [Abstract][Full Text] [Related]
39. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
[TBL] [Abstract][Full Text] [Related]
40. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]